Company intelligence / Profile preview
Autonomous Therapeutics
Rockville, Maryland, United Statesautonomous.bio ↗
- Ownership
- Private
- Employees
- ~20
- Development stage
- Preclinical
01
Overview
Autonomous Therapeutics has developed a proprietary pipeline of more than ten encrypted RNA™ candidates targeting both infectious disease and oncology. Their lead programs include next-generation immunotherapies such as AT313—a cancer-targeted RNA prodrug designed to eliminate tumor cells while sparing healthy tissue. The company’s technologies have shown promise in preclinical models, with a Phase I trial in treatment-refractory metastatic solid tumors planned through a partnership with MiNK Therapeutics. The company has received significant non-dilutive funding from DARPA, NIH, OSD, BARDA/JLABS Blue Knight™, and venture capital.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Encrypted RNA™ (encRNA) therapeuticsmRNA-based medicinesImmunotherapies (including cancer and antiviral)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
MiNK Therapeutics – collaboration to develop therapies targeting metastatic tumors using combined iNKT cell therapy and encRNA technology; planning joint clinical trials.Funders/partners include DARPA, NIH, OSD, Third Kind Venture Capital (3kVC), BARDA/JLABS Blue Knight™ initiative.
Beyond the preview
Go deeper on Autonomous Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Autonomous Therapeutics.